Aptose Announces Closing Of $3 Million Investment By Hanmi Pharmaceutical
Amount Raised
$3 Million
Round Type
Seed
San DiegoBiotechnologyHealth CareMedicalTherapeuticsresearchDescription
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced closing of a $3 million investment in common shares of the Company (the “Shares”) as the first tranche of a private equity investment for up to a maximum of $7 million or 19.99 percent ownership interest by Hanmi Pharmaceutical, Inc. (“Hanmi”), Seoul, South Korea. Under the terms of the strategic investment, Hanmi purchased each Share at a price of $4.488, representing a premium over Aptose’s common stock price.
Fundz sees it the moment Aptose Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Aptose Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.